Extended Data Fig. 1: Physiological parameters at 21 days of DOCA-salt HTN.
(A-B) Tissue sodium (A) and potassium (B) content was assessed by inductively coupled plasma – atomic emission spectrometry (ICP-AES)75,76. Intergroup differences analyzed by unpaired two-tailed t-test for each organ, n = 6–10 mice/group as shown. (C-D) BBB permeability (D) assessed by brain extravasation of 3 kDa FITC-dextran (C) quantified by spectrophotometry in brain homogenates revealed no impairment during DOCA-salt hypertension (n = 5–8). (E-F) DOCA-salt HTN does not impair resting CBF assessed quantitatively by arterial spin label (ASL)-MRI (control (E) n = 10 mice, DOCA (F) n = 9 mice) at 21 days of treatment in the hippocampus (Hipp), cortex (Ctx), amygdala (Amyg), caudate putamen (CP), thalamus (Thal), or hypothalamus (Hypoth). Intergroup differences analyzed by two-way ANOVA with Tukey’s multiple comparisons test. (G) IL17-GFP+ neutrophils were not changed by DOCA-salt in peripheral blood mononuclear cells (PBMC) or in the dura. n = 4/group.
